ArticleCell2022
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.
Open access · greenAbstract read
In one paragraph
Article in Cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 435 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
435citing papers in PubMed, 1 pooled it
55.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
435 citing papers in PubMed, 1 synthesis or guideline pooled it, 614 citations in OpenAlex.
- A meta-analysis identifies driver genes and characterizes the molecular epidemiology of colorectal cancer.Scientific reports · 2026Pooled it
- A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number-High/p53-Abnormal Endometrial Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer.JCI insight · 2025Trial
- Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study.Breast cancer research : BCR · 2025Trial
- Whole genome sequencing of 378 prostate cancer metastases reveals tissue selectivity for mismatch deficiency with potential therapeutic implications.Genome medicine · 2025Trial
- IRDRM: Exploring Biological Traits and Clinical Significance in Breast Cancer Through Gene Pairs and Somatic Mutation Profiles.Interdisciplinary sciences, computational life sciences · 2026Article
- Protein Language Models Identify Early Folding Residues as Critical Hotspots for Pathogenic Variants and Cancer Prognosis.International journal of molecular sciences · 2026Article
- Prognostic Impact of Organ-Specific Metastasis in Non-Small-Cell Lung Cancer.Cancer research and treatment · 2026Article
- Clinical metastatic cancer from initiation to colonization: emerging challenges and breakthroughs.Oncogene · 2026Review
- From bench to bedside: the evolving role of iodine in thyroid cancer management.Nature reviews. Endocrinology · 2026Review
- Review
- Actionable genetic landscape and dynamics in circulating DNA from 12,827 patients with metastatic breast cancer.Nature communications · 2026Article
- Article
- DUSP1 is a key driver of disease persistence and potential therapeutic target in hairy cell leukemia.Blood advances · 2026Article
- Quantifying uncertainty of predictions from cancer progression models.Bioinformatics (Oxford, England) · 2026Article
- Evolving patterns of co-mutations from tumor initiation to metastatic progression.Nature genetics · 2026Article
- Charting intratumor heterogeneity from bench to bedside.Nature cancer · 2026Review
- Liquid biopsies reveal dual compartments of cancer risk from tumor and host-derived mutations.Bioinformatics (Oxford, England) · 2026Article
- Gene mutant dosage is associated with prognosis and metastatic tropism in 60,000 clinical cancer samples.Nature genetics · 2026Article
- A tumour-host feed-forward loop contributes to the growth of chromosomal instability-induced tumours.EMBO reports · 2026Article
375 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
75 authors at 3 institutions in 1 country.
Bastien NguyenMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Christopher FongMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Anisha LuthraMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Shaleigh A SmithMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Renzo G DiNataleMolecular Pharmacology Program, Sloan Kettering Institute, New York, NY, USA; Urology and Renal Transplantation Service, Virginia Mason Medical Center, Seattle, WA, USA.
Subhiksha NandakumarMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Henry WalchMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Walid K ChatilaMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ramyasree MadupuriMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ritika KundraMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Craig M BielskiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Medical College at Cornell University, New York, NY, USA.
Brooke MastrogiacomoMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mark T A DonoghueMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Adrienne BoireHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Neurology and Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sarat ChandarlapatyHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Karuna GaneshMolecular Pharmacology Program, Sloan Kettering Institute, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
James J HardingWeill Medical College at Cornell University, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Christine A Iacobuzio-DonahueHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Pedram RazaviWeill Medical College at Cornell University, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ed ReznikMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Charles M RudinMolecular Pharmacology Program, Sloan Kettering Institute, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Dmitriy ZamarinWeill Medical College at Cornell University, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Wassim AbidaDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ghassan K Abou-AlfaDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Carol AghajanianDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andrea CercekDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ping ChiDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Darren FeldmanDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alan L HoDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Gopakumar IyerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yelena Y JanjigianDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael MorrisDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Robert J MotzerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Eileen M O'ReillyDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael A PostowDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nitya P RajDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Gregory J RielyDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mark E RobsonDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jonathan E RosenbergDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Anton SafonovDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alexander N ShoushtariDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
William TapDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Min Yuen TeoDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Anna M VargheseDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Martin VossDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rona YaegerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Marjorie G ZaudererDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nadeem Abu-RustumDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Julio Garcia-AguilarDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Bernard BochnerDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abraham HakimiDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
William R JarnaginDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
David R JonesDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Daniela MolenaDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Luc MorrisDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Eric Rios-DoriaDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Paul RussoDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Samuel SingerDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Vivian E StrongDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Debyani ChakravartyDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lora H EllensonDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Anuradha GopalanDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jorge S Reis-FilhoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Britta WeigeltDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Marc LadanyiDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mithat GonenDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sohrab P ShahDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Joan MassagueCancer Biology and Genetics Program, Sloan Kettering Institute, New York, NY, USA.
Jianjiong GaoMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ahmet ZehirDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael F BergerMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
David B SolitMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Medical College at Cornell University, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Samuel F BakhoumHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Francisco Sanchez-VegaDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: sanchezf@mskcc.org.
Nikolaus SchultzMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: schultzn@mskcc.org.
Memorial Sloan Kettering Cancer Center · USKettering University · USVirginia Mason Medical Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTargeting Oncogenic Pathways in Genetically Complex SarcomasP50CA217694 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Marc Ladanyi · 2018 to 2026
$21.5MTargeting Polθ to Overcome PARP Inhibitor Resistance in Homologous Recombination Deficient Breast CancerP50CA247749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Sarat Chandarlapaty, Simon N. Powell · 2020 to 2026
$16.3MSPORE in Bladder CancerP50CA221745 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI OSTROVNAYA, IRINA · 2018 to 2024
$11.8MSPORE in Soft Tissue SarcomaP50CA140146 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SPRIGGS, DAVID R · 2010 to 2014
$11.1MProbing cytosolic nucleic acid sensing pathways in cancerR01CA256188 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LAUGHNEY, ASHLEY MARIE · 2021 to 2025
$3.5MUnderstanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST)U01CA252048 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHI, PING · 2021 to 2025
$3.1MMechanisms of Dynamic Transcriptional Reprogramming in Metastasis Stem CellsR37CA266185 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Karuna Ganesh · 2022 to 2026
$2.6MEpigenetic mechanisms of transcriptional activation of a novel oncogenic ALK variant in cancerR01CA228216 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHI, PING · 2018 to 2022
$2.5MThe role of chromosomal instability in tumor evolutionDP5OD026395 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI BAKHOUM, SAMUEL F · 2018 to 2022
$2.2MDefining mechanisms of resistance to hormonal therapy in breast cancerR01CA234361 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHANDARLAPATY, SARAT, SOLIT, DAVID B. · 2019 to 2023
$2.0MInvestigating Microenvironmental Interactions in Leptomeningeal MetastasisR01CA245499 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BOIRE, ADRIENNE A. · 2020 to 2024
$2.0MNCI NIH HHS K08 CA230213NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA140146NCI NIH HHS P50 CA217694NCI NIH HHS P50 CA221745NCI NIH HHS P50 CA247749NCI NIH HHS R01 CA228216NCI NIH HHS R01 CA234361NCI NIH HHS R01 CA245499NCI NIH HHS R01 CA256188NCI NIH HHS R37 CA266185NCI NIH HHS U01 CA252048NIH HHS DP5 OD026395
Abstract
Metastatic progression is the main cause of death in cancer patients, whereas the underlying genomic mechanisms driving metastasis remain largely unknown. Here, we assembled MSK-MET, a pan-cancer cohort of over 25,000 patients with metastatic diseases. By analyzing genomic and clinical data from this cohort, we identified associations between genomic alterations and patterns of metastatic dissemination across 50 tumor types. We found that chromosomal instability is strongly correlated with metastatic burden in some tumor types, including prostate adenocarcinoma, lung adenocarcinoma, and HR+/HER2+ breast ductal carcinoma, but not in others, including colorectal cancer and high-grade serous ovarian cancer, where copy-number alteration patterns may be established early in tumor development. We also identified somatic alterations associated with metastatic burden and specific target organs. Our data offer a valuable resource for the investigation of the biological basis for metastatic spread and highlight the complex role of chromosomal instability in cancer progression.
Indexed as
GenomicsHigh-Throughput Nucleotide SequencingCohort StudiesFemaleHumansMaleNeoplasm MetastasisOrgan SpecificityProspective Studiescancerclinical sequencingDNA sequencinggenomicsmetastasismolecular profilingmutationsnext-generation sequencingorganotropismpan-cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.